Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand?
Heart failure is still a major cause of hospitalization and mortality in developed countries. Many clinical trials have tested the use of multipotent stem cells as a cardiac regenerative medicine. The benefit for the patients of this therapeutic intervention has remained limited. Herein, we review the pluripotent stem cells as a cell source for cardiac regeneration. We more specifically address the various challenges of this cell therapy approach. We question the cell delivery systems, the immune tolerance of allogenic cells, the potential proarrhythmic effects, various drug mediated interventions to facilitate cell grafting and, finally, we describe the pathological conditions that may benefit from such an innovative approach. As members of a transatlantic consortium of excellence of basic science researchers and clinicians, we propose some guidelines to be applied to cell types and modes of delivery in order to translate pluripotent stem cell cardiac derivatives into safe and effective clinical trials.
INSERM UMR-S999, LabEx LERMIT, IPSIT Centre Chirurgical Marie Lanelongue, Le Plessis Robinson, Paris, France.
Elodie
E
Gouadon
INSERM GMGF, a UMRS_910, Université Aix Marseille, Marseille, France.
Thomas
T
Moore-Morris
Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, Amsterdam, The Netherlands.
Nicoline W
NW
Smit
INSERM U1151, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Lucienne
L
Chatenoud
Department of Clinical and Experimental Cardiology, Academic Medical Center, Amsterdam, Amsterdam, The Netherlands.
Ruben
R
Coronel
Imperial College, London, United Kingdom.
Sian E
SE
Harding
INSERM UMR-S999, LabEx LERMIT, IPSIT Centre Chirurgical Marie Lanelongue, Le Plessis Robinson, Paris, France.
Philippe
P
Jourdon
INSERM UMR-S999, LabEx LERMIT, IPSIT Centre Chirurgical Marie Lanelongue, Le Plessis Robinson, Paris, France.
Virginie
V
Lambert
INSERM UMR-S999, LabEx LERMIT, IPSIT Centre Chirurgical Marie Lanelongue, Le Plessis Robinson, Paris, France.
Catherine
C
Rucker-Martin
INSERM GMGF, a UMRS_910, Université Aix Marseille, Marseille, France.
Michel
M
Pucéat
D000818:Animals; D002454:Cell Differentiation; D004195:Disease Models, Animal; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009206:Myocardium / Q000166:cytology*; D039904:Pluripotent Stem Cells / Q000166:cytology*; D033581:Stem Cell Transplantation
Cardiac; Cellular therapy; Embryonic stem cells; Pluripotent stem cells; Progenitor cells; Tissue regeneration